Johnson & Johnson’s Novel Targeted Oral Peptide Shines in Phase II Trial for Plaque Psoriasis

JNJ-2113, an oral IL-23–receptor antagonist peptide, showed consistency across clinician and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Source link
#Johnson #amp #Johnsons #Targeted #Oral #Peptide #Shines #Phase #Trial #Plaque #Psoriasis